• In late January 2026, Abbott Laboratories reported revenue and profit guidance below Wall Street expectations, highlighted ongoing weakness in its pediatric nutrition business, advanced plans for its multibillion-dollar Exact Sciences acquisition, and addressed regulatory scrutiny and a recall affecting its FreeStyle Libre glucose monitoring devices.
• Amid these setbacks, large institutional trading activity and insider share purchases, alongside continued analyst optimism about Abbott’s medical devices and biowearables, suggest investors are weighing operational challenges against the company’s broader healthcare platform and acquisition ambitions.
• With recent results, nutrition headwinds, and the planned Exact Sciences acquisition in focus, we’ll assess how this news reshapes Abbott’s investment narrative.

We've uncovered the 15 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

What Is Abbott Laboratories' Investment Narrative?

To own Abbott today, you need to believe its diversified healthcare platform, anchored by medical devices and diagnostics, can offset pressure in weaker franchises and absorb the Exact Sciences acquisition. The recent earnings miss, softer guidance, and ongoing nutrition challenges keep the near term messy, especially with management itself signaling several more difficult quarters. At the same time, the planned Exact Sciences deal, Libre Assist AI features, and new cardiac approvals keep product momentum in focus, even as the Libre recall and FDA warning letter remind investors that regulatory risk is very real in Abbott’s growth engines. The stock’s pullback, insider buying, and a large institutional block trade around US$100 suggest some investors see downside as more limited, but the legal, integration, and execution risks are now front and center in the story.

However, the Libre recall and FDA letter add a layer of risk investors should not ignore. Abbott Laboratories' shares are on the way up, but they could be overextended by 13%. Uncover the fair value now.

Exploring Other Perspectives

Ten fair value estimates from the Simply Wall St Community span roughly US$96 to US$136 per share, reflecting wide disagreement on Abbott’s worth. Set that against the recent nutrition headwinds, Libre recall issues, and acquisition uncertainty, and you can see why different investors may reach very different conclusions about its future performance.

Explore 10 other fair value estimates on Abbott Laboratories - why the stock might be worth as much as 25% more than the current price!

Build Your Own Abbott Laboratories Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Abbott Laboratories research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Abbott Laboratories research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Abbott Laboratories' overall financial health at a glance.

Seeking Other Investments?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Uncover the next big thing with 25 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.